NO964015L - Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer - Google Patents

Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer

Info

Publication number
NO964015L
NO964015L NO964015A NO964015A NO964015L NO 964015 L NO964015 L NO 964015L NO 964015 A NO964015 A NO 964015A NO 964015 A NO964015 A NO 964015A NO 964015 L NO964015 L NO 964015L
Authority
NO
Norway
Prior art keywords
calpain
activation
detecting
identifying
inhibitors
Prior art date
Application number
NO964015A
Other languages
English (en)
Other versions
NO964015D0 (no
Inventor
Robert Siman
Donna Bozyzko-Coyne
Original Assignee
Cephalon Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cephalon Inc filed Critical Cephalon Inc
Publication of NO964015L publication Critical patent/NO964015L/no
Publication of NO964015D0 publication Critical patent/NO964015D0/no

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/81—Protease inhibitors
    • C07K14/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • C07K14/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Neurology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Neurosurgery (AREA)
  • Rehabilitation Therapy (AREA)
  • Rheumatology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Denne oppfinnelse tilveiebringer fremgangsmåter for påvisning av kalpain-aktivering ved måling av nivået av kalpain-genererte spektrin BDP'er ved anvendelse av anti- stoffer som spesifikt binder seg til disse spektrin BDP'er, men ikke til intakt spektrin, eller til spektrin BDP'er generert av andre proteaser. Også inkludert i denne oppfinnelse er en kit for diagnostisering av syk- dommer assosiert med øket nivå av kalpain-aktivering, og fremgangsmåter til screening for effektive terapeutika for disse sykdommer.
NO964015A 1994-03-25 1996-09-24 Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer NO964015D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,989 US5536639A (en) 1994-03-25 1994-03-25 Methods for detecting calpain activation by detection of calpain activated spectrin breakdown products
PCT/US1995/002279 WO1995026506A1 (en) 1994-03-25 1995-02-21 Methods for detecting calpain activation and indentifying calpain inhibitors

Publications (2)

Publication Number Publication Date
NO964015L true NO964015L (no) 1996-09-24
NO964015D0 NO964015D0 (no) 1996-09-24

Family

ID=22813313

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964015A NO964015D0 (no) 1994-03-25 1996-09-24 Fremgangsmåte for påvisning av kalpain-aktivering og identifisering av kalpain-inhibitorer

Country Status (8)

Country Link
US (2) US5536639A (no)
EP (1) EP0752103A1 (no)
JP (1) JPH09511332A (no)
AU (1) AU1929695A (no)
CA (1) CA2185141A1 (no)
FI (1) FI963811A0 (no)
NO (1) NO964015D0 (no)
WO (1) WO1995026506A1 (no)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0910564B1 (en) * 1995-11-28 2007-10-31 Cephalon, Inc. D-amino acid derived inhibitors of cysteine and serine proteases
EP0799892A3 (en) * 1996-04-05 1998-08-12 Takeda Chemical Industries, Ltd. Calpain, its production and use
WO1998018485A1 (en) 1996-10-31 1998-05-07 Alcon Laboratories, Inc. The use of calpain inhibitors to treat ocular neural pathology
US6048703A (en) 1996-11-15 2000-04-11 Cephalon, Inc. Methods for detecting cell apoptosis
GB9704312D0 (en) * 1997-03-01 1997-04-23 Univ Nottingham Diagnostic assay
EP1116029B1 (en) * 1998-09-24 2007-12-26 Promega Corporation Apoptosis marker antibodies and methods of use
CA2367504A1 (en) * 1999-03-19 2000-09-28 Yamanouchi Pharmaceutical Co., Ltd. A screening method for a cysteine protease inhibitor
AUPQ656500A0 (en) * 2000-03-28 2000-04-20 Autogen Pty Ltd A method of treatment and agents for same
US7329489B2 (en) * 2000-04-14 2008-02-12 Matabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
WO2001078652A2 (en) * 2000-04-14 2001-10-25 Metabolon, Inc. Methods for drug discovery, disease treatment, and diagnosis using metabolomics
JP2005538380A (ja) * 2002-09-11 2005-12-15 ユニヴァーシティ オヴ フロリダ 神経細胞損傷の分析
US8492107B2 (en) 2004-04-15 2013-07-23 University Of Florida Research Foundation, Inc. Neural proteins as biomarkers for nervous system injury and other neural disorders
EP1745149A4 (en) 2004-04-15 2008-08-06 Univ Florida NEURALE PROTEINS AS BIOMARKERS FOR INJURY TO THE NERVOUS SYSTEM AND OTHER NEURAL DISORDERS
WO2005113798A2 (en) 2004-04-15 2005-12-01 University Of Florida Research Foundation, Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
US8849577B2 (en) * 2006-09-15 2014-09-30 Metabolon, Inc. Methods of identifying biochemical pathways
WO2008097618A1 (en) * 2007-02-06 2008-08-14 University Of Florida Research Foundation, Inc. Synaptotagmin and collapsin response mediator protein as biomarkers for traumatic brain injury
EP3336551B1 (en) * 2008-08-11 2023-05-31 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
US12601749B2 (en) 2008-08-11 2026-04-14 Banyan Biomarkers, Inc. Biomarker detection process and assay of neurological condition
JP2020500508A (ja) 2016-10-28 2020-01-16 バンヤン・バイオマーカーズ・インコーポレーテッド ユビキチンｃ末端ヒドロラーゼｌ１（ｕｃｈ−ｌ１）およびグリア線維酸性タンパク質（ｇｆａｐ）に対する抗体および関連する方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5118606A (en) * 1988-09-02 1992-06-02 The Regents Of The University Of California Methods for detecting cellular pathology by assaying spectrin and spectrin breakdown products
US5444042A (en) * 1990-12-28 1995-08-22 Cortex Pharmaceuticals Method of treatment of neurodegeneration with calpain inhibitors
WO1992011850A2 (en) * 1990-12-28 1992-07-23 Cortex Pharmaceuticals, Inc. Use of calpain inhibitors in the inhibition and treatment of neurodegeneration

Also Published As

Publication number Publication date
WO1995026506A1 (en) 1995-10-05
FI963811A7 (fi) 1996-09-24
AU1929695A (en) 1995-10-17
CA2185141A1 (en) 1995-10-05
FI963811L (fi) 1996-09-24
US5871712A (en) 1999-02-16
US5536639A (en) 1996-07-16
NO964015D0 (no) 1996-09-24
FI963811A0 (fi) 1996-09-24
EP0752103A1 (en) 1997-01-08
JPH09511332A (ja) 1997-11-11

Similar Documents

Publication Publication Date Title
NO331148B1 (no) Anvendelse av et monoklonalt eller polyklonalt antistoff, samt fremgangsmate og kit for in vitro diagnose.
KR950700414A (ko) 사람 인터루킨-4에 대한 사람화 모노클로날 항체의 클로닝 및 발현(Cloning and expression of humanized monoclonal antibodies against human interleukin-4)
AU3538195A (en) Assays and devices for the detection of extrahepatic biliary atresia
DE69836888D1 (de) Verfahren für Fluoreszenzerkennungstest
ATE290212T1 (de) Immunologische bestimmungen von prostata- spezifischem antigen
DE69115267D1 (de) Antigen-/antiantigenspaltung.
NO982265L (no) Diagnostikk for og mediatorer for inflammatoriske forstyrrelser
ATE473754T1 (de) Verfahren zur manipulation der zelldifferenzierung
DK0939651T3 (da) Materialer og metoder ved diagnose og behandling af præeclapsia
ATE382148T1 (de) Antikörper für apoptosemarker und anwendungsverfahren
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
FI971883A0 (fi) Vasta-aineluokkapesifinen häiriöitä estävä reagenssi
ATE221657T1 (de) Entstörung durch rheumafaktoren
FI922017A0 (fi) Immunbestaemningar och monoklonala antikroppar foer protrombinaktiveringspeptider och degradations- produkter av dessa.
FI973561A7 (fi) Menetelmä ja yhdisteitä analysoitavien aineiden määrittämiseksi remane nssimittausten avulla ja mainittujen yhdisteiden käyttö
ATE312622T1 (de) Verwendung von anti-hbp antikörper zur inhibierung der freisetzung von bradykinin
NO973823L (no) Påvisning av antistoffproduksjon
ATE186553T1 (de) Competitives enzym-testverfahren zum nachweis von phosphothioaten
DK1171157T3 (da) Anvendelse af glucose-6-phosphat-isomerase og antistoffer derimod til diagnosticering og behandling af arthritis, og test for anti-arthritis-forbindelser
DE50008417D1 (de) Verfahren zur bestimmung der avidität von antikörpern
IL141858A0 (en) Diagnostic method for detecting disturbances of the pancreas
HU9701386D0 (en) Immunoassay method
DE69524625D1 (de) Niederslagbewertungsverfahren für bacillus thuringiensis delta-toxin

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application